Login to Your Account



Allergan Licenses Neurotoxin From Korean Upstart Medytox

By Shannon Ellis
Staff Writer

Wednesday, October 9, 2013
SHANGHAI – While it works to maintain its dominant market share, the U.S.-based maker of Botox (onabotulinumtoxinA) has licensed a promising neurotoxin from a South Korean company.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription